Durata Therapeutics to Announce Full Year 2013 Financial Results on March 14, 2014
March 07 2014 - 8:00AM
Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly
conference call for Friday, March 14th at 8:30 a.m. Eastern Time to
discuss fourth quarter/full year 2013 financial results.
The conference call will be available via phone and webcast. To
access the call, please dial 866-632-4021 for participants in the
U.S. or Canada and 404-991-3968 for international callers
(reference Conference ID 31699772). A replay of the call may be
accessed through March 28, 2014 by dialing 800-585-8367 for callers
in the U.S. and Canada and 404-537-3406 for international callers
(reference Conference ID 31699772). The conference call will also
be webcast live on the Investor Relations section of the Company's
website at www.duratatherapeutics.com.
About Durata Therapeutics, Inc.
Durata Therapeutics is a pharmaceutical company focused on the
development and commercialization of novel therapeutics for
patients with infectious diseases and acute illnesses. Durata has
completed two global Phase 3 clinical trials with its lead product
candidate, dalbavancin, under investigation for the treatment of
patients with acute bacterial skin and skin structure infections
caused by susceptible Gram-positive bacteria.
Forward-looking Statements
Statements contained in this press release contain
forward-looking statements that involve substantial risks and
uncertainties. All statements, other than statements of historical
facts, contained in this press release, including statements
regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and
objectives of management, are forward-looking statements. The words
"anticipate," "believe," "estimate," "expect," "intend," "may,"
"plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Forward-looking statements in this press release include
statements about the impact of once-weekly dosing of dalbavancin.
Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, including those discussed in the "Risk Factors" section of
our most recent quarterly report on Form 10-Q, which is on file
with the SEC and is also available on our website. In addition, any
forward-looking statements represent our views only as of today and
should not be relied upon as representing our views as of any
subsequent date. While we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so, even if our views change. Therefore, you
should not rely on these forward-looking statements as representing
our views as of any date subsequent to today.
CONTACT: Investor Relations and Public Affairs Contact
Allison Wey
Durata Therapeutics
Vice President, Investor Relations and Public Affairs
(312) 219-7017
awey@duratatherapeutics.com
Media Relations Contact
Geoff Curtis
DJE Science
(312) 233-1253
geoff.curtis@djescience.com
(MM) (NASDAQ:DRTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
(MM) (NASDAQ:DRTX)
Historical Stock Chart
From Oct 2023 to Oct 2024